
SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00.
Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.

SVB Leerink has decided to maintain its Market Perform rating of Rubius Therapeutics (NASDAQ:RUBY) and lower its price target from $5.00 to $3.00.
Shares of Rubius Therapeutics are trading down 24.14% over the last 24 hours, at $2.42 per share.